Patent Pool May Be a Key Factor in Open RAN Adoption, Report Says
27.2.2023 21:45:00 EET | Business Wire | Press release
A patent pool may play a key role in the adoption of Open RAN technology, according to a recent report published by Harvard Business School Professor Josh Lerner and Bella Private Markets.
The report entitled “Accelerating innovation in connectivity: The case for an Open RAN patent pool”, which can be found here, was commissioned by Alium, a joint venture between MPEG LA and Unified Patents. Alium launched the Open RAN Patent Portfolio License last year. See https://www.alium-llc.com/blog/alium-introduces-open-ran-patent-portfolio-license
"Patent pools have historically played a critical role in supporting innovation by reducing risks around intellectual property and encouraging investment in new technologies. One such technology is Open RAN, a key component in unlocking widespread 5G adoption,” said Professor Lerner. “The Alium pool represents one effort to accelerate the adoption of Open RAN and help realize its many potential benefits."
“We appreciate the work of Josh Lerner and Bella Private Markets demonstrating a patent pool’s role in the adoption of Open RAN technology,” said Craig Thompson, a licensing executive at Alium. “While Open RAN has the potential to reshape the market for mobile telecommunications by increasing vendor diversity, lowering costs and energy consumption, facilitating wider adoption of 5G, and giving operators greater control over their networks, it relies on a crowded and complex patent landscape with little or no royalty benchmarking information. That’s where the Alium Patent Pool comes in. Based on our experience, we are confident that Alium’s Open RAN Patent Pool will reduce royalty stacking, hold-up, and expensive litigation risks, helping Open RAN implementers save billions in costs while accelerating future revenue growth, profitability, and new service deployments.”
Alium’s objective is to offer worldwide access to as many Open RAN essential patents as possible to everyone on the same terms under a single license. Alium welcomes the participation of any party with at least one patent that is essential to the Open RAN Standard. For more information, please go to https://www.alium-llc.com/licensors.
Josh Lerner and Bella Private Markets
Bella Private Markets focuses exclusively on providing solutions to the challenges facing the private capital industry. Led by Harvard Business School Professor Dr. Josh Lerner, Bella combines rigorous academic approaches with real world industry expertise to provide actionable insights for its clients. Bella focuses on complex, customized projects that require thorough analysis, whether quantitative or qualitative in nature, to help its clients improve performance, optimize operations, and chart winning strategies for the future.
Alium
Alium, a joint venture between MPEG LA and Unified Patents, supports Open RAN with the first patent pool for telecommunications infrastructure. Open RAN provides network operators with greater control and flexibility in deploying 4G and next generation 5G networks, and the Alium patent pool provides a one-stop solution to the uncertainty and risk posed by as many as tens of thousands of patents owned by numerous patent owners that cover the 3GPP standardized lower physical layer functionalities performed by radio units applying the O-RAN Alliance’s 7-2x baseband architecture split.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230227005684/en/
Contact information
Tom O’Reilly
Alium
Tel: 303.200.1710
tom@alium-llc.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces the European Commission Approval of Zynyz ® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 23:42:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meury, President and Chief Executive Officer, Incyte. “As the first PD-1 immunotherapy approved in Europe in combination with platinum-based chemotherapy in the first-line setting, Zynyz helps expand the standard-of-care options available to clinicians and underscores our commitment to delivering innovative medicines that can have an impact for patients.” The EC decision follows the January 2026 positive opinion received from the European Medicines Agency’s Committee f
Dfns Launches Payouts6.3.2026 22:27:00 EET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 21:23:00 EET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 19:30:00 EET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
Sutherland Launches FinAI Hub to Industrialize Agentic AI for Banking and Financial Services6.3.2026 15:00:00 EET | Press release
Today, Sutherland announced the launch of Sutherland FinAI Hub, an enterprise Agentic AI platform built exclusively for Banking and Financial Services. As financial institutions accelerate AI adoption, many initiatives remain confined to pilots, unable to scale across legacy systems and core operations. Sutherland FinAI Hub is designed to help close that gap. FinAI Hub is an innovation ecosystem where Sutherland works with clients to design, prototype, and scale Agentic AI workflows across core operations. At launch, the platform brings together a large and expanding workforce of domain-trained AI agents purpose-built for financial institutions, supporting functions across retail banking, payments, cards, consumer and commercial lending, servicing, back office, risk and compliance functions. These modular agents can operate independently or be orchestrated across end-to-end workflows spanning onboarding, KYC, AML, fraud, underwriting, payments, disputes, servicing, and collections. For
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
